VTI Naturalvue contact lens trial update

Visioneering Technologies Inc (VTI) reported that two thirds of Naturalvue multifocal one day contact lens (NVMF) patients had experienced no meaningful progression of myopia after a year.

First year data from the three year Protect clinical trial, presented at the Las Vegas Global specialty lens symposium on January 18, found that 45% of patients had no progression and 64% experienced no meaningful progression (-0.25D or less).

Children wearing NVMF contact lenses showed an average myopia change of 0.17 D and the average refractive error reduction was 71%, or 0.41 D versus the control group. 

The average axial length reduction was 61%, or 0.17 mm versus control group, while children wearing NVMF contact lenses showed an average axial length change of 0.11 mm.